
Australia's largest pharmaceutical company has brushed off investor concerns after Donald Trump announced massive tariffs on medicines shipped to the United States.
It remains unclear whether CSL would be directly impacted by the US president's proposed 100 per cent tariffs, which he announced in a post on social media.